Pol F. Boudes

Chief Medical Officer at Galectin Therapeutics, Inc.

Pol F. Boudes

Pol F. Boudes

Chief Medical Officer at Galectin Therapeutics, Inc.

Overview
RelSci Relationships

898

Number of Boards

2

Birthday

1958

Age

62

Relationships
RelSci Relationships are individuals Pol F. Boudes likely has professional access to. A relationship does not necessarily indicate a personal connection.

President & Chief Executive Officer, Director at Protalix BioTherapeutics Inc.

Relationship likelihood: Strong

Founder at Protalix Ltd.

Relationship likelihood: Strong

Former President, Chief Executive Officer & Director at Protalix BioTherapeutics Inc.

Relationship likelihood: Strong

President & Chief Executive Officer at CymaBay Therapeutics, Inc.

Relationship likelihood: Average

Senior Vice President & Chief Scientific Officer at CymaBay Therapeutics, Inc.

Relationship likelihood: Average

Co-Founder at Milo Biotechnology LLC

Relationship likelihood: Average

Former Member, Scientific Advisory Board at Abeona Therapeutics, Inc.

Relationship likelihood: Average

Senior Vice President, Manufacturing & Nonclinical Development at CymaBay Therapeutics, Inc.

Relationship likelihood: Average

Senior Vice President, Business Development at CymaBay Therapeutics, Inc.

Relationship likelihood: Average

Vice President, Finance at CymaBay Therapeutics, Inc.

Relationship likelihood: Average

Paths to Pol F. Boudes
Potential Connections via
Relationship Science
You
Pol F. Boudes
Chief Medical Officer at Galectin Therapeutics, Inc.
Memberships
Member
Current

To further the interests of the medical profession by promoting the art and science of medicine and the betterment of public health.

Member
Current

The American Diabetes Association is leading the fight to Stop Diabetes® and its deadly consequences and fighting for those affected by diabetes. The Association funds research to prevent, cure and manage diabetes; delivers services to hundreds of communities; provides objective and credible information; and gives voice to those denied their rights because of diabetes. Founded in 1940, the Association's mission is to prevent and cure diabetes, and to improve the lives of all people affected by diabetes.

Member
Current

The Royal Society of Medicine provides postgraduate medical education. The Society provides a range of educational activities and opportunities for doctors, dentists and veterinary surgeons, including students, and for allied healthcare professionals. It also promotes an exchange of information and ideas on the science, practice and organization of medicine, both within the health professions and with responsible and informed public opinion. The Society was founded in 1805 and is headquartered in London, the United Kingdom.

Career History
Chief Medical Officer
2020 - Current

Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease and cancer. Its programs target the development of carbohydrate molecules which offers offer alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.

Chief Medical Officer
2014 - 2019

CymaBay Therapeutics, Inc. is a clinical stage biopharmaceutical company, focused on developing and providing access to therapies for patients with liver and other chronic diseases with high unmet medical need. Its products include MBX-8025 and Arhalofenate, MBX-8025 aims to treat lipid and liver diseases while Arhalofenate intends to reduce gout flares and serum uric acid. The company was founded on October 5, 1988 and is headquartered in Newark, CA.

Chief Medical Officer
2009 - Prior

Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. It is committed to expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. The firm has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Cranbury, NJ.

Transactions
Details Hidden

CymaBay Therapeutics, Inc. raised money in a private placement transaction

Details Hidden

Amicus Therapeutics, Inc. raised money in a private placement transaction

Details Hidden

Amicus Therapeutics, Inc. raised money in a private placement transaction

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Pol F. Boudes. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Pol F. Boudes's profile does not indicate a business or promotional relationship of any kind between RelSci and Pol F. Boudes.